Patient Portal

Premal H. Thaker, MD, MS

Professor, Obstetrics and Gynecology
Director, Gynecological Oncology Clinical Research
Division of Gynecologic Oncology

Specialty Areas

Cervical Cancer
Gynecologic Oncology
Ovarian Cancer
Endometrial Cancer

Board Certifications

Gynecologic Oncology
Obstetrics and Gynecology

Hospital Affiliations

Barnes-Jewish Hospital
Missouri Baptist Medical Center
Progress West Hospital

Areas of Clinical Interest

Gynecologic oncology, endometrial cancer, vulvar carcinoma, cervical cancer, ovarian cancer, adnexal masses, tumors, hysterectomy, ob/gyn, women's health, lymphadenectomy, endometrial adenocarcinomas, cervical intraepithelial neoplasia, laparoscopy, gynecologic malignancies

  • Location(s)
  • Education
  • Publication & Research
  • Financial Disclosures

Location(s)

Location(s)

Missouri Baptist Medical Center
Building D

3023 N. Ballas Road
Fourth Floor, Suite 450
St. Louis, MO 63131

Suite: Suite 450
Office Phone: 314-996-6075
Fax: 314-996-6074

Center for Advanced Medicine
Gynecologic Treatment Center

4921 Parkview Place
St. Louis, MO 63110

Suite: C
Floor: 13
Office Phone: 314-362-3181
Fax: 866-282-1113

Education

Education

Fellowship: Gynecologic Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 2006
Residency: Obstetrics and Gynecolgy, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania 2002
M.S.: Cancer Biology, University of Texas Graduate School of Biomedical Sciences, Houston, Texas 2004
Medical Degree: Allegheny University-Medical College of PA, Philadelphia, Pennsylvania 1997
B.A.: Biology, Villanova University, Villanova, Pennsylvania 1995

Publication & Research

Publication & Research

A fellow-run clinic achieves similar patient outcomes as faculty clinics: A safe and feasible model for gynecologic oncology fellow education.
Buchanan TR, Johns EA, Massad LS, Dick R, Thaker PH, Hagemann AR, Fuh KC, McCourt CK, Powell MA, Mutch DG, Kuroki LM
Gynecol Oncol. 2020 Jul 18; pii: S0090-8258(20)33653-2. doi: 10.1016/j.ygyno.2020.07.018.

PMID:
    32694061
    [PubMed - as supplied by publisher]
Related citations


Epithelial-mesenchymal transition polarization in ovarian carcinomas from patients with high social isolation.
Lutgendorf SK, Penedo F, Goodheart MJ, Dahmoush L, Arevalo JMG, Thaker PH, Slavich GM, Sood AK, Cole SW
Cancer. 2020 Jul 21; doi: 10.1002/cncr.33060.

PMID:
    32691853
    [PubMed - as supplied by publisher]
Related citations


Long-term outcomes of intensity-modulated radiation therapy (IMRT) and high dose rate brachytherapy as adjuvant therapy after radical hysterectomy for cervical cancer.
Contreras J, Srivastava A, Chundury A, Schwarz JK, Markovina S, Thaker PH, Massad LS, Mutch DG, Powell MA, Grigsby PW, Lin AJ
Int J Gynecol Cancer. 2020 Jun 11; pii: ijgc-2020-001412. doi: 10.1136/ijgc-2020-001412.

PMID:
    32527770
    [PubMed - as supplied by publisher]
Related citations


Adenomyosis presenting as a molar pregnancy: A case report.
Bedrick BS, Kazarian GS, Greenwade MM, Spies N, Chen T, Maluf H, Dicke J, Thaker PH
Gynecol Oncol Rep. 2020 May; 32100573. doi: 10.1016/j.gore.2020.100573.

PMID:
    32373693
    [PubMed]
Related citations


FIGO 2018 staging criteria for cervical cancer: Impact on stage migration and survival.
Grigsby PW, Massad LS, Mutch DG, Powell MA, Thaker PH, McCourt C, Hagemann A, Fuh K, Kuroki L, Schwarz JK, Markovina S, Lin AJ, Dehdashti F, Siegel BA
Gynecol Oncol. 2020 Jun; 157(3)639-643. doi: 10.1016/j.ygyno.2020.03.027.

PMID:
    32248993
    [PubMed - in process]
Related citations


Is hormonal therapy after risk-reducing salpingo-oophorectomy associated with an increased risk of malignancy in pathogenic variant carriers?
Mills KA, Joshi TV, West L, Kuznicki M, Kent L, Hokenstad AN, Cripe JC, Woolfolk C, Senter L, Bakkum-Gamez JN, Wenham RM, Cohn DE, Bae-Jump V, Thaker PH
Gynecol Oncol. 2020 Jun; 157(3)706-710. doi: 10.1016/j.ygyno.2020.02.033.

PMID:
    32143914
    [PubMed - in process]
Related citations


Modified frailty index is predictive of wound complications in obese patients undergoing gynecologic surgery via a midline vertical incision.
Mullen MM, Porcelli BP, Cripe J, Massad LS, Kuroki LM, Novetsky AP, Wan L, Powell MA, Mutch DG, Thaker PH
Gynecol Oncol. 2020 Apr; 157(1)287-292. doi: 10.1016/j.ygyno.2019.11.008.

PMID:
    32001077
    [PubMed - in process]
Related citations


Encyclopedia of endometriosis: a pictorial rad-path review.
Mason BR, Chatterjee D, Menias CO, Thaker PH, Siegel CL, Yano M
Abdom Radiol (NY). 2020 Jun; 45(6)1587-1607. doi: 10.1007/s00261-019-02381-w.

PMID:
    31919647
    [PubMed - in process]
Related citations


Low rates of cascade genetic testing among families with hereditary gynecologic cancer: An opportunity to improve cancer prevention.
Griffin NE, Buchanan TR, Smith SH, Leon AA, Meyer MF, Liu J, Tabak RG, Fuh KC, Thaker PH, Powell MA, Mutch DG, Massad LS, Colditz GA, Hagemann AR
Gynecol Oncol. 2020 Jan; 156(1)140-146. doi: 10.1016/j.ygyno.2019.11.005.

PMID:
    31780235
    [PubMed - indexed for MEDLINE]
Related citations


Imaging biomarkers of adiposity and sarcopenia as potential predictors for overall survival among patients with endometrial cancer treated with bevacizumab.
Gillen J, Mills KA, Dvorak J, Zheng B, Thai T, Salani R, Cosgrove CM, Davidson B, Thaker PH, Moore KN
Gynecol Oncol Rep. 2019 Nov; 30100502. doi: 10.1016/j.gore.2019.100502.

PMID:
    31720357
    [PubMed]
Related citations


Impact of tumor histology on detection of pelvic and para-aortic nodal metastasis with <sup>18</sup>F-fluorodeoxyglucose-positron emission tomography in stage IB cervical cancer.
Lin AJ, Wright JD, Dehdashti F, Siegel BA, Markovina S, Schwarz J, Thaker PH, Mutch DG, Powell MA, Grigsby PW
Int J Gynecol Cancer. 2019 Nov; 29(9)1351-1354. doi: 10.1136/ijgc-2019-000528.

PMID:
    31473660
    [PubMed - indexed for MEDLINE]
Related citations


Patients with endometrial cancer continue to lack understanding of their risks for cancer.
Sekhon S, Massad LS, Hagemann AR, Dick R, Leon A, Zamorano AS, Thaker PH, McCourt CK, Mutch DG, Powell MA, Kuroki LM
Gynecol Oncol Rep. 2019 Aug; 29106-110. doi: 10.1016/j.gore.2019.07.013.

PMID:
    31467962
    [PubMed]
Related citations


Recurrence, death, and secondary malignancy after ovarian conservation for young women with early-stage low-grade endometrial cancer.
Matsuo K, Cripe JC, Kurnit KC, Kaneda M, Garneau AS, Glaser GE, Nizam A, Schillinger RM, Kuznicki ML, Yabuno A, Yanai S, Garofalo DM, Suzuki J, St Laurent JD, Yen TT, Liu AY, Shida M, Kakuda M, Oishi T, Nishio S, Marcus JZ, Adachi S, Kurokawa T, Ross MS, Horowitz MP, Johnson MS, Kim MK, Melamed A, Machado KK, Yoshihara K, Yoshida Y, Enomoto T, Ushijima K, Satoh S, Ueda Y, Mikami M, Rimel BJ, Stone RL, Growdon WB, Okamoto A, Guntupalli SR, Hasegawa K, Shahzad MMK, Im DD, Frimer M, Gostout BS, Ueland FR, Nagao S, Soliman PT, Thaker PH, Wright JD, Roman LD
Gynecol Oncol. 2019 Oct; 155(1)39-50. doi: 10.1016/j.ygyno.2019.08.007.

PMID:
    31427143
    [PubMed - indexed for MEDLINE]
Related citations


Risk of cervical and vaginal dysplasia after surgery for vulvar intraepithelial neoplasia or cancer: A 6 year follow-up study.
Buchanan TR, Zamorano AS, Massad LS, Liu J, Thaker PH, Powell MA, Mutch DG, Kuroki LM
Gynecol Oncol. 2019 Oct; 155(1)88-92. doi: 10.1016/j.ygyno.2019.07.017.

PMID:
    31375270
    [PubMed - indexed for MEDLINE]
Related citations


Prospective pilot trial with combination of propranolol with chemotherapy in patients with epithelial ovarian cancer and evaluation on circulating immune cell gene expression.
Ramondetta LM, Hu W, Thaker PH, Urbauer DL, Chisholm GB, Westin SN, Sun Y, Ramirez PT, Fleming N, Sahai SK, Nick AM, Arevalo JMG, Dizon T, Coleman RL, Cole SW, Sood AK
Gynecol Oncol. 2019 Sep; 154(3)524-530. doi: 10.1016/j.ygyno.2019.07.004.

PMID:
    31353053
    [PubMed - indexed for MEDLINE]
Related citations


Type II endometrial cancers with minimal, non-invasive residual disease on final pathology: What should we do next?
Mills KA, Lopez H, Sun L, Cripe JC, Litz T, Thaker PH, Powell MA, Mutch DG, Fuh KC
Gynecol Oncol Rep. 2019 Aug; 2920-24. doi: 10.1016/j.gore.2019.05.007.

PMID:
    31193699
    [PubMed]
Related citations


Do gynecologic oncology patients with severely diminished renal function and urinary tract obstruction benefit from ureteral stenting or percutaneous nephrostomy?
Liang B, Lange SS, Massad LS, Dick R, Mills KA, Hagemann AR, McCourt CK, Thaker PH, Fuh KC, Mutch DG, Powell MA, Kuroki LM
Gynecol Oncol Rep. 2019 May; 28136-140. doi: 10.1016/j.gore.2019.04.007.

PMID:
    31061871
    [PubMed]
Related citations


Oxytocin in the tumor microenvironment is associated with lower inflammation and longer survival in advanced epithelial ovarian cancer patients.
Cuneo MG, Szeto A, Schrepf A, Kinner EM, Schachner BI, Ahmed R, Thaker PH, Goodheart M, Bender D, Cole SW, McCabe PM, Sood AK, Lutgendorf SK, Mendez AJ
Psychoneuroendocrinology. 2019 Aug; 106244-251. doi: 10.1016/j.psyneuen.2019.04.007.

PMID:
    31005045
    [PubMed - indexed for MEDLINE]
Related citations


Wound Complication Rates After Vulvar Excisions for Premalignant Lesions.
Mullen MM, Merfeld EC, Palisoul ML, Massad LS, Woolfolk C, Powell MA, Mutch DG, Thaker PH, Hagemann AR, Kuroki LM
Obstet Gynecol. 2019 Apr; 133(4)658-665. doi: 10.1097/AOG.0000000000003185.

PMID:
    30870300
    [PubMed - indexed for MEDLINE]
Related citations


GOG 8020/210: Risk stratification of lymph node metastasis, disease progression and survival using single nucleotide polymorphisms in endometrial cancer: An NRG oncology/gynecologic oncology group study.
Brooks RA, Tritchler DS, Darcy KM, Lankes HA, Salani R, Sperduto P, Guntupalli S, DiSilvestro P, Kesterson J, Olawaiye AB, Moxley K, Waggoner S, Santin A, Rader JS, Kizer NT, Thaker PH, Powell MA, Mutch DG, Birrer MJ, Goodfellow PJ
Gynecol Oncol. 2019 May; 153(2)335-342. doi: 10.1016/j.ygyno.2019.02.028.

PMID:
    30827726
    [PubMed - indexed for MEDLINE]
Related citations

Financial Disclosures

Financial Disclosures

Disclosure of Financial Interests with Industry

Washington University and its physicians and health professionals are committed to ensuring integrity and objectivity in medical decision-making. Some of our physicians and health professionals work collaboratively with pharmaceutical, medical device or other medical care related companies to develop innovative ideas and products that can improve health care delivery and clinical outcomes for patients. In some instances, our physicians and health professionals have an ownership or potential ownership interest in a commercial company; and/or are paid by a commercial company to provide advice on product design or to speak about the use of medications, devices, equipment or procedures. These payments may include: a) compensation for consulting and speaking engagements, b) equity, and/or c) royalties for products invented by our faculty. Any payments to Washington University physicians or health professionals must be based on tangible services and may not exceed fair market value for their work. In addition to disclosure on this website, physicians and health professionals earning more than $10,000 per year must disclose their corporate financial relationship in writing to patients when prescribing or using that company's products.

This physician reported the following financial interests during calendar year 2019:

Company Name: Celsion

Royalties:

Equity: Yes

Consulting/Advisory Board: $10,000 - $19,999

Speaker Fees:

Reporting Date: May 01, 2020


Company Name: Tesaro

Royalties:

Equity: No

Consulting/Advisory Board: $1 - $9,999

Speaker Fees: $10,000 - $19,999

Reporting Date: May 01, 2020


Company Name: Merck & Corporation

Royalties:

Equity: No

Consulting/Advisory Board: $1 - $9,999

Speaker Fees: $10,000 - $19,999

Reporting Date: May 01, 2020


Company Name: AstraZeneca

Royalties:

Equity: No

Consulting/Advisory Board:

Speaker Fees: $60,000 - $79,999

Reporting Date: May 01, 2020